TY - CHAP M1 - Book, Section TI - Renal Replacement Therapy for Acute Kidney Injury in the Intensive Care Unit A1 - Côté, Jean Maxime A1 - Koyner, Jay L. A1 - Murray, Patrick T. A2 - Schmidt, Gregory A. A2 - Kress, John P. A2 - Douglas, Ivor S. PY - 2023 T2 - Hall, Schmidt and Wood’s Principles of Critical Care, 5th Edition AB - KEY POINTSThe main goals of renal replacement therapy (RRT) for acute kidney injury (AKI) are to provide solute clearance and homeostasis (electrolytes, acid–base, and volume status), while personalizing renal support to facilitate other aspects of care of the critically ill patient (fluid balance, nutritional support, etc.).Indications for initiation of RRT for AKI should be conservative; in the absence of emergency indications, a strategy of watchful waiting should be taken.In the setting of AKI, no specific RRT modality provides a proven mortality benefit over another. However, specific clinical scenarios (e.g., acute liver failure, increased intracranial pressure, severe hemodynamic instability) may mandate a particular approach.In the setting of AKI, a minimum dose of 20 to 25 mL/kg/h of continuous renal replacement therapy (CRRT) should be delivered. Data on dosing of intermittent dialysis suggest prescription of a minimum Kt/Vurea of 1.2 per treatment three times a week. Additional treatments may be required for volume control or inadequate solute clearance.Regarding anticoagulation to maintain the extracorporeal circuit function, options include heparin, citrate, and no anticoagulation. Each has its own risks and benefits. In continuous modalities, citrate is associated with longer filter lifespan.In the setting of AKI requiring RRT, nutritional support for proteins and energy should follow the current ASPEN guidelines. For micronutrients and vitamins, data are lacking to recommend a particular approach.Depending on the modality and intensity of RRT, dosing strategies for medications (including antimicrobials) differ significantly. Adherence to dosing guidelines ensures that the targeted therapeutic dose is delivered, as inappropriate dosing has a significant impact on patient outcomes and increases the risk of mortality. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/09/18 UR - accessanesthesiology.mhmedical.com/content.aspx?aid=1201808929 ER -